Trials / Completed
CompletedNCT01977859
BNP Pharmacodynamics and Effects on Metabolism in Lean and Obese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- AdventHealth Translational Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to collect data to help researchers better understand the various causes of obesity, which may lead to the development of new obesity treatment options.
Detailed description
Obesity is major metabolic health concern and the potential beneficial effects of natriuretic peptides, specifically B-type natriuretic peptide (BNP) on adipocyte biology, energy expenditure and body weight could be of great significance. This study will provide insight into the mechanisms of dysregulation of the natriuretic peptides system in obesity and will contribute to delineate the roles and the clinical importance of BNP in the treatment of obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nesiritide | |
| DRUG | Saline |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2016-02-15
- Completion
- 2017-02-28
- First posted
- 2013-11-07
- Last updated
- 2018-02-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01977859. Inclusion in this directory is not an endorsement.